Imelda — Clinical Trial Site

62 Registered trials

27 Currently recruiting

Organisation

Imelda

Location

Bonheiden, Belgium

Identifier

ORG-100040025

Address

Imeldalaan 9, 2820, Belgium

Departments

1101: Gastro-enterologie
3002: Neurology
Associatie Dialyse Endocrinologie
BE10003: Oncologie
Cardiac Surgery
Cardiologie
Cardiology
Center for Reproductive Medicine
Digestive Oncology
Endocrinologie
Endocrinology
Endocrinology and Nephrology
Gastro-enterologie
Gastro-Enterology
Gastro-oncology
Gastroenterology
Gastroenterology & Hepatology
Gastroenterology and Hepatology
GI Clinical Research Center
gynaecology
Imelda GI Clinical Research Center
Imeldaziekenhuis Bonheiden - Department of Gastroenterology
Intensive Care Medicine
Medical Oncology
Medical Oncology and Hematology
N/A
NA
Nephrology
Neurology
Neurology Department
Oncology
Rheumatology
Thoracic and vascular Surgery

Clinical trials at this site (62)

Search interface

A Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Ended

2023-506994-36-00 Ulcerative Colitis 5 2018-10-11
Frozen-thawed embryo transfer in a natural versus artificial cycle: a randomized clinical trial. Ended

2024-511890-30-03 Subfertility 6 2018-06-26
A Placebo controlled Maintenance and Long-term Extension Study of the Efficacy and Safety of Risankizumab in Participants with Crohn's Disea… Ended

2023-506399-28-00 Crohn's Disease 5 2017-11-08
A study to learn more about how well BAY 3018250 works and how safe it is for people with proximal deep vein thrombosis Ended

2023-503315-15-00 Thrombolysis of symptomatic proximal vein thrombosis 4 2023-12-20
A study to investigate response to ompenaclid combined with FOLFIRI plus bevacizumab in patients with advanced or metastatic colorectal canc… Ended

2023-503356-27-00 Metastatic colorectal cancer that is resistant to the c 4 2023-09-07
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) Ended

2022-500101-41-00 Type 2 Diabetes 6 2023-06-07
A Phase 1 Study to Evaluate the Safety and Target Engagement of EXL01 in the Maintenance of Steroid-induced Clinical Response or Remission … Ended

2022-502241-99-00 Crohn's Disease 1 2023-03-20
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis… Ended

2023-503794-38-00 Prevention of stroke or systemic embolism in atrial fib 5 2022-11-24
Study to compare overall survival (OS) between subjects who receive SBP-101 and those who do not receive SBP-101 (i.e., placebo) in combinat… Ended

2024-514714-12-00 Metastatic Pancreatic Ductal Adenocarcinoma 10 2022-11-11
VERDICT - Optimal Treatment Target in Active Ulcerative Colitis (UC) Ended

2024-514183-21-00 Ulcerative colitis 6 2021-01-15
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV… Ended

2023-507846-96-00 Type 2 Diabetes Mellitus 5 2020-06-19
Nivo versus Nivo/Ipi or versus other chemotherapies to treat colorectal cancer Ended

2023-503956-29-00 Microsatellite Instability High (MSI-H) or Mismatch Rep 5 2019-08-26
First-line chemotherapy plus pembrolizumab and olaparib for BRCA nonmutated advanced EOC Ended

2022-502124-52-00 Advanced epithelial ovarian cancer 5 2018-12-18
RCT part: COBRA-Slim with or without fast access to TNF blockade for remission induction in early RA. LTE part: Long Term observational fol… Ended

2023-510189-28-00 Rheumatoid Arthritis 6 2018-05-15